Model-Informed Drug Development Summit on November 18-20, 2025 in Boston, United States

The Model-Informed Drug Development Summit is the first and only industry-focused, 3-day strategic meeting on how MIDD is reshaping decision-making and accelerating success in drug development. With the release of the draft ICH M15 guidelines and the FDA’s move to phase out animal testing, now is the time to embed MIDD into your strategy to accelerate regulatory approvals, cut costs, and boost clinical success.

Join senior leaders in pharmacometrics, clinical pharmacology, PK/PD, and modeling to explore and understand how to implement MIDD to help select better candidates sooner, skip phases of clinical development, personalize trials, and shape standout regulatory submissions. With real-world success stories, exclusive insights on M15, and case studies spanning a range of therapeutic areas, this summit is your one-stop shop to unlock the true potential of MIDD. Don’t miss this chance to stay ahead in a rapidly evolving landscape and drive smarter, faster, and more cost-effective drug development.

URLs:

Tickets: https://go.evvnt.com/3153295-2?pid=10008

Brochure: https://go.evvnt.com/3153295-3?pid=10008

Time: 8:00 AM - 3:45 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4197.00,

Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,

Academic and Research Institutes Pricing - 3 Day Pass (Conference + Workshop Day): USD 3597.00,

Academic and Research Institutes Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Solution and Service Providers Pricing - 3 Day Pass (Conference + Workshop Day): USD 5097.00,

Solution and Service Providers Pricing- 2 Day Pass (Conference Only): USD 3699.00

Speakers: Akshanth Polepally, Research Fellow and Director, Clinical Pharmacology, Abbvie, Anna Kondic, Vice President, Quantitative Pharmacology and Data Analytics, Bristol Myers Squibb, Ava Nguyen, Associate Director, Pharmacometrics, Neurocrine Biosciences, Cheng Chang, Director, Clinical Pharmacology, Pfizer, Husain Attarwala, Vice President, Bioanalytics, DMPK, Clinical Pharmacology and Pharmacometrics, Aera Therapeutics, Jeff Kearns, Director, Translational Modeling and Simulation, Novartis, Mahdiar Sadeghi, Senior Scientist, Denali Therapeutics, Mike Liao, Vice President, Clinical Pharmacology, Third Arc Bio, Mohamed Elmeliegy, Senior Director, Clinical Pharmacology, Pfizer, Oleg Milberg, Senior Group Director, Regeneron, Prathap Nagaraja Shastri, Scientific Director and Group Leader, Clinical Pharmacology and Pharmacometrics. Johnson and Johnson, Sarem Sarem, Co-Chair Pharmacometrics, Health Canada, Souvik Bhattacharya, Associate Director, Pharmacometrics, Astellas Pharma US, Stanley Sweeney-Lasch, Director, Merck Healthcare, Yinuo Pang, Senior Director and Senior Research Fellow, Clinical Pharmacology, Abbvie, Yongming Qu, Vice President, Research Statistics, Eli Lilly